HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
INSIDE INDUSTRY
Duke-NUS and Novo Nordisk to develop stem cell-based therapy for heart and eye diseases
This partnership of up to five years aims to develop clinical-grade stem cell derived cells to treat cardiomyopathy and macular degeneration

Cardiomyopathy is a progressive disease affecting the heart muscle. In most cases, the heart muscle deteriorates and the heart stops pumping blood, usually leading to heart failure. Cardiovascular diseases are one of the leading causes of mortality worldwide, and is responsible for nearly one in three deaths in Singapore.

Macular degeneration is a chronic irreversible medical condition that results in loss of vision because of damage to the macula, a part of the retina’s core. A person starts to go blind when the macula deteriorates. As the disease develops when a person ages, it is often referred to as age-related macular degeneration (AMD), which is a major cause of blindness in those 60 years or older. In the West, more than 30 per cent among its elderly population have some form of AMD. In Singapore, the figure is similar.

Duke-NUS Medical School (Duke-NUS) and Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, have jointly developed a novel stem cell-based therapy to treat two chronic conditions: heart failure and vision loss.

The partnership is the result of a December 2017 agreement between Duke-NUS and Novo Nordisk that will see funding support for the next three to five years from Novo Nordisk for research at Duke-NUS to study and grow heart muscle and retinal cells to treat cardiomyopathy and macular degeneration. The aims of the research, led by Duke-NUS Professor Karl Tryggvason, are to develop clinical-grade stem cell derived cells for heart muscle, and the retina. BioLamina, a Sweden-based biotechnology company, is a partner of this project and provides access to certain technologies proprietary to BioLamina.

Duke-NUS researchers have developed a novel system for growing cells in chemically defined culture systems that support stem cell self-renewal and directed differentiation of the cells. This much-improved method is also free from animal products and has been shown to form new heart muscle tissue in injured mouse heart.

Professor Tryggvason, who is also the co-founder of BioLamina, adds: “The next step for us will be to assess their suitability for human use in the appropriate pre-clinical models”.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy